As the year comes to a close, Qinecsa reflects on a successful 2025 filled with global engagement and innovation in pharmacovigilance. Our team participated in key industry events across North
Qinecsa COO, John Cogan, has been featured in European Pharmaceutical Manufacturer‘s latest article, where he discusses AI’s relevance in powering the pharmacovigilance engine. As pharmacovigilance
Molecule to Market is a podcast focused on the pharmaceutical and biotech industries, particularly the outsourcing and supply chain side of drug development. Hosted by Raman
Writers: John Fitzpatrick, Chief Technology Officer and John Cogan, Chief Operating Officer Summary In the complex and highly regulated world of pharmacovigilance (PV), the accurate
Why an AI Enhanced Approach to Pharmacovigilance Case Processing is now Non-negotiable Qinecsa CEO, Adam Sherlock has been featured in Simedics (The Journal of mHealth)
04 April 2022, London – Qinecsa Solutions announced the acquisition of MyMeds&Me Limited (MMM). Qinecsa, a leading provider of pharmacovigilance services and technologies to the
21th March 2024 —Qinecsa Solutions (Qinecsa), specialists in technology-led end-to-end pharmacovigilance solutions, proudly announce its acquisition of Insife ApS (Insife), a well-established Danish-based software, technology,
15 December 2022, London – Qinecsa Solutions UK Ltd. (Qinecsa) has announced the acquisition of Commonwealth Informatics, Inc. (Commonwealth). Qinecsa, a leading provider of pharmacovigilance
We’re proud to be featured in Applied Clinical Trials’ latest article spotlighting the future of pharmacovigilance: “Harnessing Technology and Adopting Unified Approaches to Optimize Pharmacovigilance
Effective pharmacovigilance demands continuous monitoring of drug safety signals, a critical process that ensures accurate benefit-risk assessment while meeting global regulatory requirements. This paper examines
